The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

This is a prospective, multicenter, randomized controlled clinical study to evaluate the effect of using intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment. Pyrotinib is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.

NCT Number	NCT06958627
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	HER2 Positive Breast Cancer, Pyrotinib Treatment
Enrollment	964 participants
Start Date	2024-04-30
Primary Completion	2025-04-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-06